跳至主要内容
临床试验/ACTRN12605000211662
ACTRN12605000211662已完成2 期

Intravitreal triamcinolone injection for treatment of clinically significant diabetic macular oedema that persists after laser treatment

Professor Mark Gillies0 个研究点目标入组 70 人开始时间: 2005年8月25日最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
70

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Treatment
盲法
Blinded (masking used)

入排标准

年龄范围
ot stated 至 ot stated(—)
性别
All

入选标准

  • Clinically significant diabetic macular oedema involving the fovea in one or both eyes (phakic and/or pseudophakic) which persists at least 3 months after adequate macular photocoagulation. Best corrected visual acuity in the affected eye(s) 6/9 or worse.

排除标准

  • Glaucoma which is uncontrolled or is controlled but with glaucomatous visual field defects. Loss of vision due to other causes (e.g. age related macular degeneration, myopic macular degeneration). Significant macular ischemia (FFA). No useful vision in fellow eye. Known allergies to triamcinolone acetate or steroids. Patient is already under systemic treatment with > 5mg prednisolone (or equivalent) daily. Intercurrent severe disease such as septicaemia. Any condition which would affect follow-up or photographic documentation (e.g. geographical, psycho-social, media opacities).

研究者

发起方
Professor Mark Gillies

相似试验